These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38525862)

  • 1. [Coumarin or DOAC in frail elderly patients with atrial fibrillation?].
    Joosten LPT; van Doorn S; Hemels MEW; Huisman MV; Rutten FH; Geersing GJ
    Ned Tijdschr Geneeskd; 2024 Jan; 168():. PubMed ID: 38525862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
    Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ
    Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial.
    Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ
    BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
    Toorop MMA; Chen Q; Kruip MJHA; van der Meer FJM; Nierman MC; Faber L; Goede L; Cannegieter SC; Lijfering WM
    J Thromb Haemost; 2022 Feb; 20(2):339-352. PubMed ID: 34779140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.
    Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A
    Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative performance evaluation of four bleeding risk scores in atrial fibrillation patients. What does the new DOAC score provide?
    Abu-Assi E; Lizancos Castro A; Cespón-Fernández M; González-Bermúdez I; Raposeiras Roubin S
    Int J Cardiol; 2024 Jul; 407():132018. PubMed ID: 38579940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study.
    Lin Y; Chao TF; Tsai ML; Tseng CJ; Wang TH; Chang CH; Lin YS; Yang NI; Chu PH; Hung MJ; Wu VC; Chen TH
    J Thromb Thrombolysis; 2024 Jan; 57(1):89-100. PubMed ID: 37605063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
    van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
    Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In older patients with AF and frailty, switching from VKA to NOAC therapy increased a composite of major or CRNM bleeding at 12 mo.
    Dunn A
    Ann Intern Med; 2024 May; 177(5):JC57. PubMed ID: 38710082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation.
    Søgaard M; Ording AG; Skjøth F; Larsen TB; Nielsen PB
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):137-146. PubMed ID: 37993415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
    Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
    Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS
    BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
    Ording AG; Søgaard M; Skjøth F; Grove EL; Lip GYH; Larsen TB; Nielsen PB
    Cancer Med; 2021 Jul; 10(13):4405-4414. PubMed ID: 34114733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.